These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8382876)

  • 21. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
    McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
    Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytomegalovirus infections in the immunocompromised transplant patient. Prevention of cytomegalovirus disease with oral acyclovir.
    Balfour HH; Fletcher CV; Dunn D
    Transplant Proc; 1991 Apr; 23(2 Suppl 1):17-9. PubMed ID: 1647558
    [No Abstract]   [Full Text] [Related]  

  • 23. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of polymerase chain reaction to provide prognostic information on human cytomegalovirus disease after liver transplantation.
    Lao WC; Lee D; Burroughs AK; Lanzani G; Rolles K; Emery VC; Griffiths PD
    J Med Virol; 1997 Mar; 51(3):152-8. PubMed ID: 9139077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acyclovir/cytomegalovirus immune globulin combination therapy for CMV prophylaxis in high-risk renal allograft recipients.
    Carrieri G; Jordan ML; Shapiro R; Scantlebury VP; Vivas C; Kusne S; Magnone M; McCauley J; Starzl TE
    Transplant Proc; 1995 Feb; 27(1):961-3. PubMed ID: 7879246
    [No Abstract]   [Full Text] [Related]  

  • 26. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
    Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
    Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection.
    Winston DJ; Imagawa DK; Holt CD; Kaldas F; Shaked A; Busuttil RW
    Transplantation; 1995 Dec; 60(11):1357-60. PubMed ID: 8525537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
    Reddy SP; Handa A; Tan L; Devaney A; Hughes D; Mason P; Friend PJ; Darby CR
    Transpl Int; 2003 Oct; 16(10):726-9. PubMed ID: 12827230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial.
    Pouteil-Noble C; Megas F; Chapuis F; Bosshard S; Colin C; Hadj-Aissa A; Pozet N; Martin X; Lefrançois N; Garnier JL; Aymard M; Touraine JL
    Transplant Proc; 1996 Oct; 28(5):2811. PubMed ID: 8908072
    [No Abstract]   [Full Text] [Related]  

  • 30. Aciclovir or ganciclovir universal prophylaxis of cytomegalovirus infection in liver transplantation: an economic analysis.
    Leong RW; Smith DW; Garas G; Beaman JM; Mitchell AW; Heath DI; House AK; Jeffrey GP
    Intern Med J; 2004 Jul; 34(7):410-5. PubMed ID: 15271175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.
    Hill JA; Hummel M; Starling RC; Kobashigawa JA; Perrone SV; Arizón JM; Simonsen S; Abeywickrama KH; Bara C
    Transplantation; 2007 Dec; 84(11):1436-42. PubMed ID: 18091519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cytomegalovirus infection in lung transplantation; current status, detection, prophylactic treatment].
    Aoe M; Tao H; Yamane M; Toyooka S; Sano Y; Okazaki M; Date H
    Kyobu Geka; 2007 Oct; 60(11):988-92. PubMed ID: 17926902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.
    Verma A; Devine S; Morrow M; Chen YH; Mihalov M; Peace D; Stock W; Pursell K; Wickrema A; Yassine M; Jessop E; van Besien K
    Bone Marrow Transplant; 2003 May; 31(9):813-6. PubMed ID: 12732890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
    Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
    Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
    Gerna G; Baldanti F; Torsellini M; Minoli L; Viganò M; Oggionnis T; Rampino T; Castiglioni B; Goglio A; Colledan M; Mammana C; Nozza F; Daniele L;
    Antivir Ther; 2007; 12(1):63-72. PubMed ID: 17503749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acyclovir prophylaxis for cytomegalovirus in liver transplant recipients.
    Singh N; Yu VL
    J Infect Dis; 1994 Jun; 169(6):1406-7. PubMed ID: 8195627
    [No Abstract]   [Full Text] [Related]  

  • 38. Cytomegalovirus disease in renal transplant recipients: an Iranian experience.
    Nemati E; Taheri S; Pourfarziani V; Einollahi B
    Exp Clin Transplant; 2008 Jun; 6(2):132-6. PubMed ID: 18816240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acyclovir to prevent cytomegalovirus infection in renal-graft recipients.
    Grundy JE; Griffiths PD
    N Engl J Med; 1989 Nov; 321(18):1268-9. PubMed ID: 2552315
    [No Abstract]   [Full Text] [Related]  

  • 40. Outcomes of lung transplantation using three different cytomegalovirus prophylactic regimens.
    Maurer JR; Snell G; deHoyos A; Kesten S; Winton T
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1434-5. PubMed ID: 8382872
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.